Obesity affects many cancer survivors and increases their risk of early death.
SPIRIT stands for Survivorship Promotion In Reducing IGF-1 Trial.
SPIRIT is a research study for cancer survivors who are overweight.
SPIRIT studies how weight loss or metformin might affect IGF-1, a marker for cancer.
It is a randomized, clinical trial that lasts 1 year.
The Maryland Cigarette Restitution Fund
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
To participate in SPIRIT, you or a loved one must be:
> A cancer survivor
>Overweight and willing to lose weight
> Not taking diabetes medications
> Able to come to our clinic in the Baltimore area
Participants are asked to provide laboratory specimens at the start of the trial.
You will be randomly assigned to one of the following three groups:
1) Self-Directed Weight Loss
> You will receive written materials about weight loss.
2) Behavioral Weight Loss
> You will have access to an interactive weight loss website and have telephone-based support from a health coach.
> You will receive metformin, a commonly used medication in patients with early type 2 diabetes.
Next, you will be asked to come to ProHealth (our clinic) for lab work:
3 months, 6 months, and 12 months after starting SPIRIT.
Benefits of Participation*
Free blood tests and blood pressure measurements
Up to $300 at the end of the study
Contributing valuable scientific information that may benefit:
OTHER CANCER SURVIVORS
Studies suggest an association between excess weight and cancer, but we don’t know why.
In some studies, a hormone produced by our body (IGF‐1) is linked to tumor growth.
Weight loss through diet and exercise might affect this hormone (IGF‐1).
Metformin, a medication commonly used to treat patients with early type 2 diabetes, might also affect this hormone (IGF‐1).
Directions to the ProHealth Trial Center
ProHealth Clinical Research Unit
1849 Gwynn Oak Ave, Suite 1
Baltimore, MD 21207
Main Phone: 410-281-1600
ProHealth is located in the Woodlawn neighborhood of Baltimore County.
From points North and South, follow the Baltimore Beltway (I-695) to EXIT 17 (Security BLVD) toward WOODLAWN.
Merge onto SECURITY BLVD (MD-122E), and turn Left onto GWYNN OAK AVE.
End at 1849 Gwynn Oak Ave, Baltimore, MD 21207.
*Note that this is a clinical trial, and as such you may or may not benefit from being in this study. You may be able to lose weight, lower your Insulin Growth Factor 1, better control your blood pressure, cholesterol, and blood sugar levels, but this cannot be guaranteed. If you take part in this study, information obtained from this research may lead to effective future treatments for lowering Insulin Growth Factor 1 and preventing cancer recurrence. If you take part in this study, you may help others in the future.